The companies estimate the total addressable market (TAM) for Qixleef to be nearly $1.7-billion by 2028. Food and Drug Administration (FDA) authorized clinical trials: (1) Reborn, a phase 2 study authorized by the FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain and (2) Plenitude, a phase 2 multicentre clinical trial authorized by the FDA to evaluate the safety and efficacy of inhaled cannabinoids to relieve uncontrolled pain in patients with advanced cancer. Qixleef is a proprietary botanical inhaled investigational new drug currently being studied in two U.S. With this project, Akanda becomes a CDMO in addition to being an EU-GMP (European Union good manufacturing practice) cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company, while Tetra secures a stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and commercialization. In addition, Akanda will act as a contract development and manufacturing organization (CDMO) for Tetra's clinical drug and commercial supply programs. with pharmaceutical-grade cannabis flower in a microdose cap form for use in a Storz & Bickel Mighty Medic vaporizer for global commercialization of Tetra's Qixleef and related products. Keep an eye on FVERAX as it may be in the beginning of a reversal.Tetra Bio-Pharma signs pot flower deal with AkandaĪKANDA TO SUPPLY TETRA BIO-PHARMA WITH PHARMACEUTICAL-GRADE CANNABIS FOR FDA TRIALS OF QIXLEEF, A POTENTIAL MULTIMILLION DOLLAR PRESCRIPTION DRUGĪkanda Corp. Bear Market Rally (-75) - FVERAX is showing some rallying power, but still remains in the confines of a long-term downtrend. THE FIRST TRUST COMBINED SERIES 467: INVESTMENT GRADE MULTI-ASSET INCO (FVERAX) Keep an eye on RIBIX as it may be in the beginning stages of a reversal. Bull Market Weakness (+75) - RIBIX is showing signs of short-term weakness, but still remains in the confines of a long-term uptrend. Mutual Fund RBC IMPACT BOND FUND CLASS I (RIBIX) Keep an eye on IDRSGD as it may be in the beginning of a reversal. Bear Market Rally (-75) - IDRSGD is showing some rallying power, but still remains in the confines of a long-term downtrend. Indonesian Rupiah/Singapore Dollar (IDRSGD) Keep an eye on JPYARS as it may be in the beginning stages of a reversal. Bull Market Weakness (+75) - JPYARS is showing signs of short-term weakness, but still remains in the confines of a long-term uptrend. Foreign Exchange Japanese Yen/Argentine Peso (JPYARS) Keep an eye on HG.Q23 as it may be in the beginning of a reversal. Bear Market Rally (-75) - HG.Q23 is showing some rallying power, but still remains in the confines of a long-term downtrend. Traders should use caution and utilize a stop order. While ZM.Q22 is showing intraday weakness, it remains in the confines of a bullish trend. Long-Term Uptrend (+90) - ZM.Q22 is in a strong uptrend that is likely to continue. Beware of choppy movement and consider a sidelines position until a stronger trend is identified. Sidelines Mode (-55) - SP500-25102010 is moving in a sideways pattern and is unable to gain momentum in either direction. Sidelines Mode (+55) - DX is moving in a sideways pattern and is unable to gain momentum in either direction.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |